Evidence map›Paper›PMID 29751583›Full record

ArticleMolecules (Basel, Switzerland)2018

Blood Pressure Lowering Effect of Cuban Policosanol is Accompanied by Improvement of Hepatic Inflammation, Lipoprotein Profile, and HDL Quality in Spontaneously Hypertensive Rats.

Kyung-Hyun Cho, Dhananjay Yadav, Suk-Jeong Kim, Jae-Ryong Kim

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Cuban Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2024
    Article
  5. Antihypertensive Effect of Milk Fermented byFood science of animal resources · 2024
    Article
  6. Consumption of Policosanol (RaydelPharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Cuban Policosanol (RaydelMolecules (Basel, Switzerland) · 2023
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Potential role of phytochemicals in metabolic syndrome prevention and therapy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kyung-Hyun ChoDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Korea. chok@yu.ac.kr.ORCID 0000-0003-1198-4140
Dhananjay YadavDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Korea. dhanyadav16481@gmail.com.
Suk-Jeong KimDepartment of Medical Biotechnology, Yeungnam University, Gyeongsan 712-749, Korea. superiorgene@ynu.ac.kr.
Jae-Ryong KimDepartment of Biochemistry and Molecular Biology, Smart-Aging Convergence Research Center, College of Medicine, Yeungnam University, Daegu 705-717, Korea. kimjr000@gmail.com.
Yeungnam University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the antihypertensive effect of policosanol on spontaneously hypertensive rats (SHR). For this, we analyzed blood pressure, blood lipid, and lipoprotein properties in male SHR after consumption of Cuban policosanol (PCO). The experimental groups were as follows: normotensive Wistar Kyoto (WKY) control, SHR group fed normal diet (ND), SHR group fed 20 mg of PCO, SHR group fed 100 mg of PCO, and SHR group fed 200 mg of PCO per kg of body weight. After eight weeks, the SHR control group showed gradual increases up to 21% in systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared with values at week 0. However, policosanol consumption had a dose-dependent reduction effect on SBP and also reduced DBP up to 17% in a dose-dependent manner. Heart rate (HR) bpm increased by six percent in the SHR control, whereas the 20 mg, 100 mg, and 200 mg of policosanol groups showed a reduction of 36%, 28%, and 34% respectively. Although serum total cholesterol (TC) level of SHR was not affected by policosanol consumption (70⁻80 mg/dL), serum triglyceride (TG) level significantly decreased in the SHR + 200 mg of PCO group. Serum high-density lipoprotein cholesterol (HDL-C) level was also significantly elevated by policosanol consumption. The % HDL-C/TC ratio was elevated in the policosanol group up to 67⁻70%, whereas the SHR control group showed a ratio of 58%. Serum cholesteryl ester transfer protein (CETP) activity was reduced by policosanol in a dose-dependent manner. Although the serum glutamate oxaloacetate transaminase (GOT)/ glutamate pyruvate transaminase (GPT) were similar across all groups, policosanol consumption caused reduction of reactive oxygen species (ROS) levels in hepatic tissue. The SHR control group showed a 2.1-fold higher serum C-reactive protein (CRP) level than the WKY group, whereas the CRP level decreased in the SHR + 200 mg of PCO group (up to 45%) than SHR control group. Aldosterone level was reduced in the policosanol group (up to 34%) in a dose-dependent manner compared to the control. In conclusion, eight weeks of policosanol consumption in SHR resulted in remarkable reduction of blood pressure, serum aldosterone, and serum TG levels along with the elevation of HDL-C and improvement of hepatic inflammation.

Indexed as

AnimalsAnticholesteremic AgentsAntihypertensive AgentsAntioxidantsBlood PressureBody WeightCholesterol, HDLDose-Response Relationship, DrugFatty AlcoholsHeart RateLipid MetabolismLipoproteinsLiverRatsRats, Inbred SHRAnticholesteremic AgentsAntihypertensive AgentsAntioxidantsCholesterol, HDLFatty AlcoholsLipoproteinspolicosanolhepatic inflammationhypertensionlipoproteinspolicosanolspontaneously hypertensive rats

Identifiers

PMID29751583
PMCPMC6102548
OpenAlexW2802783458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.